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Should pre-NIPT genetic counselling for sex chromosome aneuploidies be obligatory? A clinical audit of 5409 mixed risk pregnancies Objectives: The objective of this study was to analyse the uptake of SCA screening after pre-test genetic counselling among women who had NIPT and determine the performance of NIPT for SCA in our sample population. Methods: A large obstetrics and gynecology ultrasound practice (Monash Ultrasound for Women -MUFW) from Melbourne, Australia, has offered NIPT (Harmony TM ) since March 2013. All women referred to non-invasive prenatal testing (NIPT) between 10-11 weeks had a pre-test viability/dating scan and genetic counselling, where SCA screening was discussed and offered as an optional panel. A first trimester morphogy scan at 12-13 weeks was offered to all, together with NIPT post-testing counselling. Invasive procedure (CVS/amniocentesis) was offered to all high risk cases. Results: Data from 5409 mixed-risk women who had NIPT between March 2013 and December 2015 was analysed. Of those who were eligible for SCA screening, 19.7% were IVF conceptions. Overall, 20% of women declined SCA screening following genetic counselling. Method of conception and a priori risk did not influence uptake of SCA screening. Of those who had SCA screening, 36 received a high-risk assessment: 16.7% true positives, 47.3% false positives, 36% declined further testing. The false positive rate for the SCA panel was significantly higher than the false positive rates for the autosomal aneuploidies and the addition of SCA panel increased the screen positive rate in 1%. Conclusions: Given the high rate of women declining SCA screening, the low uptake of invasive procedure after a high risk result and the low number of true positive results observed on our sample, we conclude that pre-test counselling is essential and SCA screening should continue to be offered as an optional aspect of NIPT. Objectives: To determine the analytical performance of a targeted microarray based cfDNA test (Harmony Prenatal Test ® ) for the identification of pregnancies at increased risk for a 22q11.2 deletion. Methods: 1736 plasma samples were studied. 122 samples had a 22q11.2 deletion ranging in size from 1.96 to 3.25 Mb. These included simulated pregnancy samples and maternal plasma from pregnancies with a fetal 22q11.2 deletion. The simulated samples were created with plasma from individuals with 22q11.2 deletions titrated with plasma from unaffected, non-pregnant women to simulate fetal fractions ranging from 4% to 33%. 1614 samples were from women with presumed unaffected pregnancies in which the maternal and fetal 22q11.2 deletion status was unknown. Cell-free DNA analysis using Digital ANalysis of Selected Regions (DANSR TM ) was performed as previously described with additional assays for assessment of fetal 22q11.2 deletions within a 3.0 Mb region. DANSR products were quantified on custom microarrays and the probability of a deletion being present was determined using the FORTE TM algorithm.
Results:
Of the 122 samples with a 22q11.2 deletion, 92 were determined to have a high probability of a deletion (sensitivity: 75.4%; 95% CI: 67.1-82.2%). No evidence of a deletion was observed in 1606 of the 1614 samples from presumed unaffected pregnancies (specificity: 99.5%; 95% CI: 99.0-99.7%). Conclusions: Targeted cell-free DNA testing using microarray quantitation is able to identify pregnancies at increased risk for 22q11.2 deletions of 3.0 Mb and smaller while maintaining a low false positive rate.
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Changes in the utilisation of prenatal screening and diagnosis of chromosomal abnormalities in the era of cell-free DNA
